Liquidia.com

Site Inspections

Overview & More informations

Liquidia Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel products for the treatment of severe and life-threatening conditions. The Company's proprietary PRINT® (Particle Replication In Non-wetting Templates) technology allows the production of uniform, solid dose particles with a narrow size distribution and controlled morphology. This technology enables the precise formulation of drugs with optimized solubility and bioavailability, resulting in improved therapeutic efficacy and reduced side effects.

The Company's lead product candidate, LIQ861, is an inhaled dry powder formulation of Treprostinil, a prostacyclin analog currently used for the treatment of pulmonary arterial hypertension (PAH). Treprostinil is a potent vasodilator that targets the prostacyclin (IP) receptor on vascular smooth muscle cells, leading to vasodilation, inhibition of platelet aggregation, and reduced inflammation. By delivering Treprostinil directly to the lungs, LIQ861 is designed to improve efficacy and reduce systemic side effects associated with intravenous and subcutaneous delivery methods.

In addition to LIQ861, the Company is developing other product candidates for the treatment of other severe and life-threatening conditions, including severe asthma, allergic rhinitis, and diabetic macular edema. The Company's pipeline leverages the PRINT® platform to formulate a range of therapeutics with improved solubility, bioavailability, and targeted delivery.

Liquidia Technologies has a strong intellectual property portfolio, with over 160 patents issued or pending worldwide. The Company has also established strategic partnerships with ведущими фармацевтическими компаниями, такими как AbbVie и AstraZeneca, to accelerate the development and commercialization of its products.

The Company is headquartered in Research Triangle Park, North Carolina, and has operations in the United States, Europe, and Asia.

Domains Expiration Date Updated